| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. | Chief Executive Officer, Director | Common Stock, par value $0.01 per share | 750K | $1.31M | $1.75 | May 16, 2025 | Direct |
| Odyssey Health, Inc. | Chief Commerical Officer | Stock Option (Right to Buy) | 37.5K | $3.19K | $0.09 | Jan 16, 2024 | Direct |
| Apimeds Pharmaceuticals US, Inc. | Chief Executive Officer, Director | Stock option (right to buy) | 347K | May 16, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| APUS | Apimeds Pharmaceuticals US, Inc. | May 16, 2025 | 2 | $0 | 4 | May 20, 2025 | Chief Executive Officer, Director |
| APUS | Apimeds Pharmaceuticals US, Inc. | Mar 4, 2025 | 0 | $0 | 3 | May 8, 2025 | Chief Executive Officer, Director |
| ODYY | Odyssey Health, Inc. | Jan 16, 2024 | 1 | $3.19K | 4 | Jan 18, 2024 | Chief Commerical Officer |
| ODYY | Odyssey Health, Inc. | Dec 29, 2023 | 1 | $20K | 4 | Jan 2, 2024 | Chief Commerical Officer |
| ODYY | Odyssey Health, Inc. | Nov 1, 2022 | 2 | $150K | 4 | Nov 23, 2022 | Chief Commercial Officer |
| ODYY | Odyssey Health, Inc. | Nov 1, 2022 | 0 | $0 | 3 | Nov 23, 2022 | Chief Commercial Officer |